Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 7
Submit an article Journal homepage
221
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial

Sebastian GrosickiDepartment of Hematology and Cancer Prevention in Chorzow, Faculty of Health Sciences Bytom, Silesian Medical University in Katowice, Katowice, Poland; View further author information
,
Ewa Lech-MarandaDepartment of Hematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland; View further author information
,
Kanakasetty Govind BabuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, HCG Hospitals Bangalore, Bengaluru, India; View further author information
,
Justyna RybkaDepartment of Medical Oncology, Wrocław Medical University, Wrocław, Poland; View further author information
,
Elena LitvinskayaRussian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation; View further author information
,
Javier LoscertalesHospital Universitario de La Princesa, IIS-IP, Madrid, Spain; View further author information
,
Iryna KriachokOncohematology Department, National Cancer Institute, Kiev, Ukraine; View further author information
,
Janusz KłoczkoDepartment of Hematology, Medical University of Bialystok, Poland; View further author information
,
Grygoriy RekhtmanKhmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine; View further author information
,
Wojciech HomendaDepartment of Hematology and Pomeranian Academy in Slupsk, Department of Health Sciences, The Janusz Korczak State Hospital in Slupsk, Medical University of Bialystok, Bialystok, Poland; View further author information
,
Jerzy BlonskiDepartment of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland; View further author information
,
Tommaso StefanelliNovartis Pharma AG, Basel, Switzerland; View further author information
,
Ghislaine VincentNovartis Pharma S.A.S., Paris, France; View further author information
,
Hiya BanerjeeNovartis Oncology, East Hanover, NJ, USAView further author information
&
Tadeusz RobakDepartment of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland; Correspondence[email protected]
View further author information
 show all
Pages 1748-1751 | Received 10 Oct 2019, Accepted 15 Feb 2020, Published online: 28 Feb 2020

References

  • Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793–1800.
  • Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756–1765.
  • Zenz T, Busch R, Fink A, et al. Genetics of patients with F-refractory CLL or early relapse after FC or FCR: results from the CLL8 trial of the GCLLSG. Blood. 2010;116(21):2427.
  • Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362–371.
  • Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4(3):e114–e126.
  • Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–850.
  • Cramer P, von Tresckow J, Bahlo J, et al. CLL2-BXX phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018;14(6):499–513.
  • Robak T, Warzocha K, Govind Babu K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017;58(5):1084–1093.
  • Leblond V, Aktan M, Ferra Coll CM, et al. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. Haematologica. 2018;103(11):1889–1898.
  • Brown JR, O’Brien S, Kingsley CD, et al. Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. Blood. 2019;133(9):990–992.
  • Brown JR, O’Brien S, Kingsley CD, et al. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood. 2015;125(18):2779–2785.
  • Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–1363.
  • Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.